Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pidotimod→

Pidotimod Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
121808-62-6
Molecular formula
C9H12N2O4S
Molecular weight
244.27 g/mol
Drug class
Synthetic immunostimulantimmunomodulatory dipeptide
Mechanism of action
Modulates innate and adaptive immune responses, including dendritic-cell maturation, expression of co-stimulatory molecules, T-helper-1 polarisation, natural-killer-cell activity and phagocytosis. The relative contribution of these effects to clinical benefit is not fully established.
Indications / reported uses
  • Used as an adjunct in some countries for recurrent respiratory infections, particularly in selected children or patients with recurrent infections; evidence and authorisation vary by jurisdiction.

Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC6710962/ · https://pubmed.ncbi.nlm.nih.gov/?term=pidotimod+clinical+trials · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pidotimod Environmental Risk Assessment (ERA) (the Pidotimod ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.